![]() |
市場調查報告書
商品編碼
1466219
人類微生物組市場:按疾病、技術、產品、治療領域、應用分類 - 全球預測 2024-2030Human Microbiome Market by Disease (Acute Diarrhea, Autoimmune Disorders, Cancer), Technology (16s rRNA Sequencing, Cell Culture Technology, Computational Tools), Product, Therapeutic Area, Application - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
2023年人類微生物組市場規模預計為15.8億美元,預計2024年將達到19.6億美元,2030年將達到71.1億美元,複合年成長率為23.90%。
人類微生物組是存在於人體內的微生物基因組的集合。這包括細菌、古細菌、病毒和真核微生物。人體含有數兆個微生物細胞,影響身體功能和健康。幫助消化食物,抵抗病原體,並發展免疫系統。同時,慢性病盛行率的上升以及將微生物組與各種健康狀況聯繫起來的研究需求進一步推動了對基於微生物組的診斷和治療的需求。營養領域對微生物組的需求不斷成長,推動了對人類微生物組支持和影響整體健康和免疫功能的需求。然而,與活生物治療產品核准相關的監管障礙以及理解和操縱微生物組的複雜性給主要參與者帶來了重大挑戰。本公司繼續專注於研發 (R&D) 活動以及具有成本效益且易於使用的定序技術,以最佳化業務成長。此外,新治療劑開發的重大進展和投資增加正在為全球地區營運的主要企業創造重大機會。人工智慧 (AI) 和高級機器學習 (ML) 等開發的關鍵技術正在與微生物組研究相結合,以更好地了解複雜的微生物相互作用並開發新的治療解決方案。
主要市場統計 | |
---|---|
基準年[2023] | 15.8億美元 |
預測年份 [2024] | 19.6億美元 |
預測年份 [2030] | 71.1億美元 |
複合年成長率(%) | 23.90% |
技術 16s rRNA定序和體學技術的最新進展使研究人體內的分子因素和過程成為可能
16s 核醣體 RNA定序是一種廣泛使用的技術,用於識別和比較樣本中的細菌。它重點關注 16S rRNA 基因,該基因是原核核醣體 30S 小次單元的組成部分,在不同物種的細菌和古細菌中高度保守。這項技術可以幫助研究人員對細菌進行分類並確定其譜系,從而深入了解微生物組的組成。另一方面,細胞培養技術涉及在受控條件下(通常在自然環境之外)培養細胞。在微生物組研究中,細胞培養技術使我們能夠分離和維持微生物以進行研究。包括次世代定序儀(NGS) 在內的高通量技術徹底改變了微生物群落研究的速度和規模。這些技術可以同時對數百萬個 DNA 分子進行定序,從而全面了解微生物組的多樣性和功能。此外,元基因組分析可以分析從環境樣本中獲得的遺傳物質,從而消除了研究人員在實驗室培養生物體的需要。這項技術對於研究人類微生物組很有用,因為它可以對所有存在的微生物的遺傳物質進行獨立於培養的檢查,甚至是那些不易在試管內生長的微生物。此外,基因組學、轉錄組學、蛋白質組學和代謝體學等體學技術提供了對生物系統的整體情況和高解析度見解。在微生物組研究中,這些技術詢問各種分子因素和過程,包括基因組 RNA 轉錄物、蛋白質體學和微生物群落的代謝物。
應用擴大人類微生物組在各種健康狀況的醫療保健診斷和治療中的應用
人類微生物組是存在於人體內部和表面的微生物基因組的集合,其在診斷方面的潛力是一個越來越受關注的領域。次世代定序儀和生物資訊學的進步使研究人員能夠將特定的微生物組成和活性與各種健康狀況聯繫起來。在診斷領域,分析人類微生物組有助於識別發炎性腸道疾病、糖尿病和某些癌症等疾病的生物標記。在治療領域,人類微生物群透過基於微生物群的療法提供了個人化醫療的潛力。糞便微生物移植(FMT)用於透過恢復健康的微生物平衡來治療困難梭狀芽孢桿菌傳染病。
區域洞察
在美洲,在先進的微生物組研發和商業化的推動下,美國和加拿大的人類微生物組經歷了顯著成長,許多公司積極致力於開發基於微生物組的治療方法和診斷方法。該地區的人類微生物組景觀正在穩步發展,研究重點是了解微生物組對人類健康和疾病的影響。同時,歐洲國家政府對微生物組研究展現了強力的支持,並建立了許多舉措和研究聯盟。歐洲的法律規範正在不斷發展,以支持微生物組資料和產品的安全和道德的使用。中東和非洲地區是人類微生物組產品不斷成長的市場,這主要是由於與文明病的增加和醫療保健支出的增加。同時,由於人們越來越認知到微生物平衡對整體健康的重要性、醫療保健成本不斷上升以及微生物基因組學的進步,亞太地區人類微生物組市場正在顯著成長。該地區益生菌、益生元和合合益素的研究和開發正在不斷發展,特別是為了解決胃腸道疾病和慢性病等當地健康問題。
FPNV定位矩陣
FPNV定位矩陣對於評估人類微生物組市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對人類微生物組市場供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該行業競爭特徵的寶貴見解,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,從而在市場上獲得競爭優勢。
1. 市場滲透率:提供有關主要企業所服務的市場的全面資訊。
2. 市場開拓:我們深入研究利潤豐厚的新興市場,並分析其在成熟細分市場的滲透率。
3. 市場多元化:提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4.競爭評估與資訊:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。
5. 產品開發與創新:提供對未來技術、研發活動和突破性產品開發的見解。
1. 人類微生物組市場的市場規模與預測是多少?
2.在人類微生物組市場的預測期間內,有哪些產品、細分市場、應用和領域需要考慮投資?
3.人類微生物組市場的技術趨勢和法規結構是什麼?
4.人類微生物組市場主要廠商的市場佔有率是多少?
5. 進入人類微生物組市場的適當型態和策略手段是什麼?
[198 Pages Report] The Human Microbiome Market size was estimated at USD 1.58 billion in 2023 and expected to reach USD 1.96 billion in 2024, at a CAGR 23.90% to reach USD 7.11 billion by 2030.
The human microbiome is the collective genomes of the microorganisms that reside on and inside the human body. These include bacteria, archaea, viruses, and eukaryotic microbes. The human body hosts trillions of these microbial cells, which can influence bodily functions and health. It assists in the digestion of food, protection against pathogens, and the development of the immune system. Meanwhile, the rise in chronic disease prevalence and a growing need for research linking the microbiome to various health conditions further stokes demand for microbiome-based diagnostics and therapeutics. The growing need for a microbiome in nutrition propels the demand for a human microbiome to support and influence overall wellness and immune function. However, the regulatory hurdles associated with approving live biotherapeutic products and complexities in comprehending and manipulating the microbiome present a significant challenge for the key players. Companies are continuously focusing on research and development (R&D) activities and cost-effective and accessible sequencing technologies to optimize their business growth. Moreover, the advancements in developing novel human microbiome therapeutics and rising investments present a significant opportunity for the key companies operating in the global space. Emerging technologies such as artificial intelligence (AI) and advanced machine learning (ML) are integrated with microbiome research to understand complex microbial interactions better and develop novel therapeutic solutions.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 1.58 billion |
Estimated Year [2024] | USD 1.96 billion |
Forecast Year [2030] | USD 7.11 billion |
CAGR (%) | 23.90% |
Technology: Recent advancements in 16s rRNA sequencing and omics technology to investigate molecular factors and processes in human body
16s ribosomal RNA sequencing is a widely used method for identifying and comparing bacteria within a sample. It focuses on the 16S rRNA gene, a component of the 30S small subunit of prokaryotic ribosomes, which is highly conserved within different species of bacteria and archaea. This technique helps researchers classify and determine the phylogeny of bacteria, providing insights into the microbiome's composition. On the other hand, cell culture technology involves growing cells under controlled conditions, typically outside their natural environment. In microbiome research, cell culture technology allows scientists to isolate and maintain microorganisms for study. High-throughput technologies, including next-generation sequencing (NGS), have revolutionized the speed and scale at which microbial communities can be studied. These methods allow for the simultaneous sequencing of millions of DNA molecules, offering a comprehensive view of the microbiome's diversity and function. Moreover, metagenomic sequencing analyzes the genetic material obtained from environmental samples, helping researchers bypass the need to cultivate organisms in the lab. This technology helps study the human microbiome by allowing for a culture-independent examination of the genetic material of all microorganisms present, including those not easily cultured in vitro. Furthermore, omics technologies, such as genomics, transcriptomics, proteomics, and metabolomics, provide holistic views and high-resolution insights into biological systems. In microbiome research, these technologies investigate various molecular factors and processes, such as the genomics RNA transcripts, proteomics, and metabolites of microbial communities.
Application: The increasing adoption of the human microbiome in healthcare diagnostics and therapeutics to cater to various health conditions
The human microbiome, comprised of the collective genome of microorganisms residing in and on the human body, has become an area of increasing interest for its potential in diagnostics. Advancements in next-generation sequencing and bioinformatics have allowed researchers to correlate specific microbial compositions and activities with various health conditions. For diagnostics, analysis of the human microbiome facilitates the identification of biomarkers for diseases such as inflammatory bowel disease, diabetes, and certain types of cancer. In the therapeutic domain, the human microbiome offers the potential for personalized medicine through microbiota-based treatments. Fecal microbiota transplantation (FMT) is used to treat clostridium difficile infections by restoring a healthy microbial balance.
Regional Insights
In the Americas, the United States and Canada witnessed significant growth in human microbiome driven by the research and commercialization of advanced microbiome, with numerous companies actively engaged in developing microbiome-based therapies and diagnostics. The human microbiome landscape in this region is steadily growing, focusing on research aimed at understanding the impact of the microbiome on human health and disease. On the other hand, European countries exhibit strong government support for microbiome research with numerous initiatives and research consortia in place. The regulatory framework in Europe is evolving to support the safe and ethical use of microbiome data and products. The Middle East and Africa region represents a growing market for human microbiome products, primarily driven by an increasing burden of lifestyle diseases and growing healthcare expenditure. At the same time, the human microbiome landscape in the Asia-Pacific region is experiencing significant growth, driven by increasing awareness of the importance of microbial balance to overall health, rising healthcare expenditures, and advancements in microbial genomics. Research and development in probiotics, prebiotics, and symbiotics are growing in this region, particularly in addressing regional health issues such as gastrointestinal disorders and chronic diseases.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Human Microbiome Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Human Microbiome Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Human Microbiome Market, highlighting leading vendors and their innovative profiles. These include AOBiome, LLC, Astarte Medical Partners, Inc, Axial Therapeutics, Inc., Azitra, BiomeSense, Inc., BiomX Ltd., DuPont de Nemours, Inc., Enterome Bioscience, Evelo Biosciences, Inc., Exeliom Biosciences SAS, Ferring B.V., Finch Therapeutics Group, Inc., Illumina, Inc., Intralytix, Inc., Invivo Healthcare, Locus Biosciences, Inc., Merck KGaA, Metabiomics Corporation, Osel Inc., Rebiotix Inc., Second Genome, Inc., Seres Therapeutics, Inc., Synlogic, Inc., Theriva Biologics, Inc., Vedanta Biosciences, Inc., Viome Life Sciences, Inc., and Yakult Honsha Co., Ltd..
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Human Microbiome Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Human Microbiome Market?
3. What are the technology trends and regulatory frameworks in the Human Microbiome Market?
4. What is the market share of the leading vendors in the Human Microbiome Market?
5. Which modes and strategic moves are suitable for entering the Human Microbiome Market?